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Abstract
Introduction: Acute kidney injury (AKI) in the ICU is associated with poorer prognosis. Hydroxyethylstarch (HES)
solutions are fluid resuscitation colloids frequently used in the ICU with controversial nephrotoxic adverse effects.
Our study objective was to evaluate HES impact on renal function and organ failures.
Methods: This observational retrospective study included 363 patients hospitalized for more than 72 hours in our
ICU. A hundred and sixty eight patients received HES during their stay and 195 did not. We recorded patients’
baseline characteristics on admission and type and volume of fluid resuscitation during the first 3 weeks of ICU
stay. We also noted the evolution of urine output, the risk of renal dysfunction, injury to the kidney, failure of
kidney function, loss of kidney function and end-stage kidney disease (RIFLE) classification and sepsis related organ
failure assessment (SOFA) score over 3 weeks.
Results: Patients in the HES group were more severely ill on admission but AKI incidence was similar, as well as
ICU mortality. The evolution of urine output (P = 0.74), RIFLE classification (P = 0.44) and SOFA score (P = 0.23) was
not different. However, HES volumes administered were low (763+/-593 ml during the first 48 hours).
Conclusions: Volume expansion with low volume HES 130 kDa/0.4 was not associated with AKI.
Introduction
Hydroxyethylstarches (HES) are resuscitation solutes lar-
gely employed in intensive care units (ICU) [1]. How-
ever, their potential nephrotoxic effect is controversial
[2-18] and acute kidney injury (AKI) in the ICU is asso-
ciated with a 60% mortality rate [19]. The 2001 prospec-
tive randomized study by Schortgen and colleagues [5]
showed that plasma volume expansion with HES was an
independent risk factor for AKI compared with gelatins.
More recently, the volume substitution and insulin ther-
apy in severe sepsis (VISEP) study [6] compared ringer’s
lactate with HES 200 kDa/0.5 for fluid resuscitation in
patients with severe sepsis or septic shock. HES use was
associated with renal failure and increased need for
renal replacement therapy (RRT). Renal failure was
directly related to the volume of HES administered with
a dose-effect relation. Coupled with the results of
another recent study [7], some experts addressed the
question of the continuing usefulness of HES use in the
I C U[ 9 ] .H o w e v e r ,p u b l i s h e ds t u d i e sc o m p a r e dH E S
with different molecular weights, degrees of substitution
and diluents and used variable definitions of kidney fail-
ure. Therefore, we decided to conduct a practice survey
including all the patients hospitalized in our ICU during
at w o - y e a rp e r i o dt oe v a l u a t ei fp l a s m av o l u m ee x p a n -
sion with a ‘modern’ HES 130 kDa/0.4 had an impact
on kidney function according to the validated RIFLE
(Risk of renal dysfunction, Injury to the kidney, Failure
of kidney function, Loss of kidney function and End-
stage kidney disease) classification.
Materials and methods
Inclusion criteria and study goal
We included all the patients hospitalized for the first
time for more than 72 hours in the ICU of Tourcoing
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a retrospective study, in accordance with French law,
neither approval of the ethics committee nor informed
consent was required.
We evaluated the impact of volume expansion with
HES 130 kDa/0.4 on the evolution of renal function and
other organ failures during the first three weeks of
patients’ stay in our unit.
Data collection and definitions
On admission
For all the patients, the following characteristics were
collected on ICU admission:a g e ,g e n d e r ,u n d e r l y i n g
clinical conditions, severity of illness and vital sign
abnormalities. In particular, we examined if patients pre-
sented with chronic kidney disease (defined by a creati-
nine clearance <60 ml/min), and had more than one
cardiovascular underlying disease (myocardial infarction,
stroke, lower limb arteritis). We checked if patients had
systemic inflammatory reaction syndrome, sepsis or sep-
tic shock, or shock from other origin. Shock was defined
as a sustained (one hour or more) decrease in the systo-
lic blood pressure of at least 40 mmHg from baseline or
a resultant systolic blood pressure less than 90 mmHg
after adequate fluid replacement and in the absence of
any antihypertensive drug [20]. Severity of illness was
assessed by the Sepsis related Organ Failure Assessment
(SOFA) score [21] and the Simplified Acute Physiology
Score (SAPS) II [22]. Potential nephrotoxic factors were
recorded, including usual treatment by diuretics, angio-
tensin-converting enzyme (ACE) inhibitors, angiotensin-
II receptor blockers (ARBs) or non-steroidal anti-inflam-
matory drugs (NSAIDs).
Evolution
Volume expansion was quantified every 48 hours until
ICU discharge or for a maximum of three weeks. We
collected data on HES 130 kDa/0.4, crystalloids, 4%
albumin and packed red blood cells (dextrans and gela-
tins are not used in our unit and our starch is a non-
balanced solution). Plasma volume expansion did not
follow a protocol. The evolution of the SOFA score,
urine output and RIFLE [23] classification was recorded
every 48 hours during three weeks.
To evaluate the evolution of renal failure, we analyzed
two groups of patients: those with normal kidney func-
tion and those with RIFLE class ‘risk’ on admission.
Patients were considered to have AKI when the RIFLE
class increased to ‘injury’ or ‘failure’ during the three-
week follow up.
Development of a nosocomial infection or a new shock
between day 3 and day 21 was recorded. Potential AKI
risk factors were also noted: use of nephrotoxic antibio-
tics (aminoglycosides, glycopeptides), inappropriate
administration (aminoglycosides injection whereas
plasma measurement was superior to 2 μg/ml, vancomy-
cinemia superior to 30 μg/ml), exposure to radio-contrast
agents, rhabdomyolysis defined by creatine phospho
kinase (CPK) measurement superior to five times the
normal, urinary obstruction, or treatment with ampho-
tericin B or nephrotoxic chemotherapy (cisplatin or
cyclosporine). Treatment with aminoglycosides did not
exceed three days. Prognostic values were recorded:
number of days under mechanical ventilation, vasopres-
sors and RRT on day 28. Mortality was recorded in the
ICU only.
Statistical analysis
Comparisons between groups were performed using chi-
squared test or Fisher’s exact test for categorical para-
meters. Continuous variables were analysed using Wil-
coxon’s test. Differences between groups were
considered to be significant for variables yielding a
P value less than 0.05. The evolutions of urine output,
SOFA score and RIFLE class were analyzed with a linear
mixed model. All analyses were performed using the
SAS Software (SAS Institute, Version 8.2 ed. Cary,
North Carolina, USA).
Results
Between July 2006 and July 2008, 363 patients were hos-
pitalized for more than 72 hours in our ICU. One hun-
dred and sixty-eight patients (46% of the population)
received HES during the three-week follow up. Volume
expansion with crystalloids and albumin was similar in
the two groups (Table 1). We only noticed more packed
red blood cells transfusions at 48 hours in the HES
group. Half the HES volume (763 ± 595 ml) was admi-
nistered in the first 48 hours of ICU stay. Baseline char-
acteristics differed in patients who did and did not
receive HES. Particularly, patients who received HES
had more frequent surgical admissions (23.1% vs. 11.7%,
P < 0.01), higher severity scores (SAPS II: 53.5 ± 17.1
vs. 46.6 ± 16.8, P = 0.0001 and SOFA: 8.95 ± 3.2 vs.
7.38 ± 3.8, P = 0.0001), and higher incidence of shock,
mostly more septic shock (47.6% vs. 30.2%, P = 0.0007).
Follow-up characteristics also differed. Patients who
received HES had more frequent secondary shocks
(26.8% vs. 11.6%, P = 0.0003) with a longer shock dura-
tion (5.43 ± 6.1 vs. 2.63 ± 4.2 days, P = 0.0001),
increased need for vasopressors (80% vs. 48.7%,
P < 0.0001) and mechanical ventilation (90.5% versus
70.8%, P < 0.0001). Duration of mechanical ventilation
was also longer (16.9 ± 17.7 vs. 11.9 ± 17.9 days,
P = 0.008). ICU mortality was 31.1% in the HES group
versus 25.8% (P = 0.26).
The SOFA score (Figure 1) was higher in the HES group
on admission (8.95 ± 3.2 vs. 7.38 ± 3.8, P < 0.0001),
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and then the difference disappeared (P = 0.23). The RIFLE
classification (Figure 2) had the same kinetic: initially
higher in the HES group (P = 0.007), with initial improve-
ment (P < 0.0001), but lack of difference during follow up
(P = 0.44). The urine output (Figure 3) was similar on
admission (1515 ± 1269 ml vs. 1492 ± 987, P =0 . 3 7 ) ,
increased during ICU stay (P < 0.0001), without any differ-
ence between the groups (P = 0.74).
To evaluate the incidence of AKI with regard to HES
administration, we separated the patients into two
groups: the patients with normal kidney function and
those with a RIFLE class ‘risk’ on admission. The
patients who benefited from HES administration had
more cardiovascular and respiratory failures on admis-
sion, with higher gravity scores (Tables 2 and 3).
Presence of AKI risk factors and the development of
AKI was similar in patients with or without HES in the
two groups. However, patients with HES had a longer
duration of shock, mechanical ventilation and ICU stay.
There was no difference in ICU mortality (Table 3).
Discussion
Considering all the patients admitted to the ICU for
more than 72 hours, HES volume expansion did not
worsen the RIFLE class or SOFA score despite higher
RIFLE and SOFA on admission in patients receiving
HES. The groups of patients with no kidney dysfunction
or at risk of kidney injury on admission who received
HES were more severely ill; in particular, they had more
cardiovascular and respiratory failures. Development of
AKI was not different.
Figure 1 Evolution of the SOFA score during 21 days with or without HES. HES, hydroxyethylstarch; SOFA, sepsis related organ failure
assessment score.
Table 1 Cumulative dose of volume expansion after 48 hours, one week and three weeks of ICU stay
Cumulative dose of volume expansion HES - HES + P
Crystalloids on day 2 (ml) 3,180 ± 2,171 3,310 ± 2,090 0.56
HES on day 2 (ml) 0 763 ± 595 Inf 0.0001
Albumin on day 2 (ml) 89 ± 374 80 ± 280 0.78
Packed red blood cells on day 2 (n) 0.28 ± 0.86 0.66 ± 1.91 0.019
Crystalloids on day 7 6252 ± 4075 6,587 ± 3,878 0.53
HES on day 7 0 1,031 ± 800 Inf 0.0001
Albumin on day 7 153 ± 457 241 ± 715 0.27
Packed red blood cells on day 7 0.89 ± 1.85 1.4 ± 3.36 0.15
Crystalloids on day 21 10,572 ± 5,930 10,638 ± 6,638 0.96
HES on day 21 0 1,361 ± 1,393 Inf 0.0001
Albumin on day 21 266 ± 743 665 ± 1,587 0.10
Packed red blood cells on day 21 2.77 ± 3.45 3.85 ± 5.53 0.23
HES, hydroxyethylstarch.
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with a 40 to 80% mortality rate [19,24-27]. Differences
in the literature come from the variability of AKI defini-
tion [28]. This heterogeneity led to the creation of an
AKI classification, called RIFLE, by an international con-
sensus [23]. This classification has been validated in ret-
rospective studies, which also correlated the RIFLE to
mortality [29-31].
No study has demonstrated the superiority of colloids
on crystalloids on morbimortality [3] and renal toxicity
of HES has been controversial for a long time. The first
studies suggesting a toxicity were performed in renal
transplantation. In a 1993 retrospective study, Legendre
and colleagues discovered 80% osmotic lesions in renal
transplant recipients who received HES (200 kDa/0.62)
versus 14% before their utilisation [3]. Then, Cittanova
and colleagues [4] prospectively compared HES (200
kDa/0.62) with gelatins as volume expander in the
resuscitation of donor patients with brain death. RRT
need on day 8 after renal transplantation was 33% in the
HES group compared with 5% in the gelatins group.
However, these studies were criticized for their metho-
dology and unconfirmed by further studies [11,12].
Two double-blind multicenter randomized studies
found a nephrotoxicity of HES in ICU patients [5,6]. In
a study of 129 patients with severe sepsis and septic
shock [5], Schortgen and colleagues demonstrated that
HES 6% (200 kDa/0.6) was an independent risk factor
for AKI (odds ratio (OR) = 2.57) compared with gela-
tins. More recently, the VISEP study [6] compared
volume expansion with ringer’sl a c t a t ev e r s u sH E S
(200 kDa/0.5) for severe sepsis and septic shock. The
use of HES (200 kDa/0.5) was associated with an
increased incidence of renal failure (34.9% versus 22.8%,
Figure 3 Evolution of the urine output during 21 days with or without HES. HES, hydroxyethylstarch.
Figure 2 Evolution of the RIFLE classification during 21 days with or without HES. HES, hydroxyethylstarch; RIFLE, Risk of renal dysfunction,
Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease.
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and with a dose-effect relation.
Schortgen and colleagues, in a prospective cohort
study of 1013 septic shock patients, showed a 2.48 renal
failure risk increase with hyperoncotic colloid compared
with crystalloids [7]. This study used ‘modern’ HES
solutions with a low molecular weight and low substitu-
tion rate (HES 6% (130 kDa/0.4), identical to our study.
Once again, a dose-effect relation was found and renal
failure occurred when patients received more than 2000
ml of HES during 36 hours. The study also found an
increased ICU and day-28 mortality associated with
HES, and an AKI increase with 20% albumin. Another
recent study in cardiac surgery found that HES 250
kDa/0.45 was an independent AKI risk factor with a
dose-dependant relation (OR = 1.08/ml/kg infused) [10].
Table 2 Baseline characteristics of the patients with normal kidney function and RIFLE class ‘risk’ on admission broken
by HES administration
Normal kidney function on admission P RIFLE ‘risk’ on admission P
HES -
n=4 5
HES +
n=2 8
HES -
n=5 4
HES +
n=3 7
Age (years) (mean ± SD) 59.5 ± 15.9 55.8 ± 17.2 0.4 66.2 ± 13.3 64.1 ± 15.8 0.78
Male sex n(%) 32 (71.1) 20 (71.4) 0.98 41 (75.9) 26 (70.2) 0.55
Comorbidities
Chronic cardiac failure 7 (15.5) 3 (10.7) 0.73 12 (22.2) 5 (13.5) 0.29
More than one cardiovascular event 6 (13.3) 4 (14.3) 1 13 (24) 5 (13.5) 0.21
Diabete mellitus 14 (31.1) 5 (17.9) 0.2 10 (18.5) 10 (27) 0.34
COPD 13 (28.9) 8 (28.6) 0.98 16 (29.6) 12 (32.4) 0.77
Chronic liver failure 7 (15.5) 1 (3.6) 0.14 2 (3.7) 0 (0) 0.51
Chronic alcoholism 8 (17.8) 6 (21.4) 0.7 10 (18.5) 10 (27) 0.34
Chronic renal failure 2 (4.4) 2 (7.1) 0.63 3 (5.5) 3 (8.1) 0.63
Non hematologic malignancy 2 (4.4) 6 (21.4) 0.05 3 (5.5) 2 (5.4) 1
Hematologic malignancy 2 (4.4) 1 (3.6) 1 1 (1.8) 0 (0) 1
Immunosuppression 7 (15.5) 3 (10.7) 0.73 6 (11.1) 2 (5.4) 0.47
Usual treatments
ACE inhibitors/ARB 14 (31.1) 6 (21.4) 0.37 21 (38.9) 15 (40.5) 0.93
Diuretics 15 (33.3) 3 (10.7) 0.05 17 (31.5) 10 (27) 0.6
NSAIDs 2 (4.4) 0 (0) 0.52 3 (5.5) 1 (2.7) 0.64
Hospitalisation before ICU 19 (42.2) 12 (43) 0.96 24 (44.4) 10 (27) 0.09
Reason for ICU admission 0.07 0.56
Medicine 41 (91.1) 19 (68) 47 (87) 31 (83.8)
Planned surgery 1 (2.2) 3 (14.3) 0 (0) 0 (0)
Urgent surgery 2 (4.4) 4 (10.7) 6 (11.1) 6 (16.2)
Polytrauma 1 (2.2) 2 (7.1) 1 (1.8) 0 (0)
Clinical presentation
SAPS II 40.3 ± 15.9 46 ± 19.5 0.32 40.6 ± 14.6 50.3 ± 13.1 0.001
SOFA 6.1 ± 3.6 8.2 ± 3.9 0.03 6.5 ± 3.3 8.4 ± 2.3 0.001
SIRS - sepsis 14 (31.1) 9 (32.1) 0.92 22 (40.7) 11 (29.7) 0.28
Septic shock 8 (17.8) 9 (32.1) 0.16 17 (31.5) 17 (45.9) 0.16
Shock from other etiology 6 (13.3) 5 (17.9) 0.73 5 (9.2) 8 (21.6) 0.1
Bacteremia 4 (8.8) 3 (14.3) 1 6 (11.1) 5 (13.5) 0.75
Platelet count (1000/mm
3) 245 ± 155 201 ± 159 0.11 291 ± 177 253 ± 164 0.27
pH 7.36 ± 0.1 7.29 ± 0.12 0.02 7.34 ± 0.11 7.3 ± 0.12 0.15
Lactate (meq/l) 1.7 ± 1.1 2.2 ± 1.8 0.43 2.6 ± 1.6 3.4 ± 3.9 0.77
Serum urea (g/l) 0.43 ± 0.3 0.41 ± 0.31 0.68 0.58 ± 0.42 0.63 ± 0.4 0.4
Creatinine (mg/l) 9.9 ± 3.7 10.1 ± 5.9 0.49 12.5 ± 5 13.6 ± 4.8 0.42
PaO2/FiO2 258 ± 111 202 ± 131 0.04 201 ± 87 193 ± 99 0.6
ACE, angiotensin-converting-enzyme; ARB, angiotensin-II receptor blockers; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; HES,
hydroxyethylstarch; NSAIDs, non-steroidal anti-inflammatory drugs; PaO2, partial pressure of arterial oxygen; RIFLE, Risk of renal dysfunction, Injury to the kidney,
Failure of kidney function, Loss of kidney function and End-stage kidney disease; SAPS, simplify acute physiology score; SD, standard deviation; SIRS, systemic
inflammatory reaction syndrome; SOFA, sepsis related organ failure assessment score.
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compiled 34 randomized clinical trials (2607 patients)
comparing HES with other fluid therapies and found a
1 . 5f o l dr i s ko fd e v e l o p i n gA K Iw i t hH E S ,w i t ha n
increased risk in septic patients [32]. However, the
results are limited by the different definitions of AKI
and the authors insisted on the use of validated AKI
criteria.
We wanted to evaluate the impact of HES volume
expansion on renal function in our unit. Vascular
expansion with HES was not applied according to a pro-
tocol, but, looking at our results, it seems mostly used
for more critically ill patients: patients with HES had
higher severity scores and more frequent mechanical
ventilation and vasopressors. Whereas the RIFLE class
was also higher in the patients who received HES, the
evolution of renal function did not demonstrate any
deleterious effect of HES. Moreover, some could argue
that HES administered in small volumes is in fact
protective, but our study did not have the power to
draw this conclusion and only a well-designed prospec-
tive randomized study could prove a beneficial effect of
small-volume HES administration.
Similar results have already been published. A large
prospective multicenter study of more than 3000 ICU
patients found that HES administration did not increase
the need for RRT [13]. An important difference between
t h i ss t u d ya n dt h eV I S E Ps t u d yw a st h eH E Sv o l u m e
administered. In the VISEP study, the mean cumulative
dose of HES 200 kDa/0.5 was 70.4 ml/kg and volume
expansion was performed exclusively with ringer’s lactate
or HES. This is far above the manufacturer’s recommen-
d a t i o n so f3 3m l / k g / d a yo nd a y1 ,t h e n2 0m l / k g / d a y .I n
the study by Sakr and colleagues [13], the cumulative
dose was much lower, around 1000 ml in the first 48
hours, similar to the volume we used. In the post-opera-
tive setting, other studies did not find deleterious effects
of HES, even in patients with chronic renal dysfunction
Table 3 Evolution of the patients with normal kidney function and RIFLE class ‘risk’ on admission broken by HES
administration
Normal kidney function on admission P RIFLE “risk” on admission P
HES -
n=4 5
HES +
n=2 8
HES -
n=5 4
HES +
n=3 7
ICU treatments
Catecholamines n (%) 17 (37.7) 19 (67.9) 0.01 27 (50) 27 (73) 0.03
- Norepinephrine 15 (33.3) 18 (64.3) 0.01 26 (48.1) 25 (67.6) 0.07
- Epinephrine 1 (2.2) 3 (10.7) 0.12 2 (3.7) 2 (5.4) 1
- Dobutamine 3 (6.7) 4 (14.3) 0.41 3 (5.5) 4 (10.8) 0.43
Activated protein C 0 (0) 0 (0) 1 0 (0) 0 (0) 1
Hydrocortisone 7 (15.5) 7 (25) 0.7 14 (25.9) 13 (35.1) 0.92
Mechanical ventilation 28 (62.2) 24 (85.7) 0.03 36 (66.7) 33 (89.2) 0.01
Aminoglycosides 8 (17.8) 9 (32.1) 0.16 15 (27.8) 13 (35.1) 0.45
Toxic dose aminoglycosides 1 (2.2) 1 (3.6) 1 0 (0) 0 (0) 1
Glycopeptides 7 (15.5) 6 (21.4) 0.54 13 (24.1) 12 (32.4) 0.38
Toxic dose glycopeptides 1 (2.2) 0 (0) 1 3 (5.5) 1 (2.7) 0.64
Amphotericin B 0 (0) 0 (0) 1 0 (0) 0 (0) 1
Radio-contrast agents 7 (15.5) 4 (14.3) 1 5 (9.2) 5 (13.5) 0.73
Rhabdomyolysis 4 (8.9) 3 (10.7) 1 6 (11.1) 6 (16.2) 0.47
Urinary obstruction 1 (2.2) 0 (0) 1 0 (0) 1 (2.7) 0.4
Chemotherapy 0 (0) 0 (0) 1 0 (0) 1 (2.7) 0.4
Evolution
Shock from day 3 to day 21 3 (6.7) 4 (14.3) 0.41 6 (11.1) 6 (16.2) 0.54
Hemofiltration 0 (0) 2 (7.1) 0.14 3 (5.5) 3 (8.1) 0.68
AKI 5 (11.1) 5 (17.9) 0.49 6 (11.1) 3 (8.1) 0.73
Nosocomial infection 8 (17.8) 8 (28.6) 0.28 11 (20.4) 10 (27) 0.45
Duration of shock (days (mean ± SD)) 1.4 ± 2.6 4.2 ± 6.1 0.004 2.1 ± 3.1 3.8 ± 4.2 0.01
Duration of mechanical ventilation (days) 8.4 ± 11.5 16.4 ± 18.6 0.02 13.3 ± 17.2 12.8 ± 16.8 0.1
Duration of hemofiltration (days) 0 1.2 ± 4.3 0.07 0.9 ± 5.2 0.7 ± 2.8 0.38
Duration of ICU stay (days) 12.5 ± 12.7 20.2 ± 20.3 0.09 14.8 ± 16.6 15.4 ± 16.6 0.27
ICU death 9 (20) 7 (25) 0.62 12 (22.2) 12 (32.4) 0.28
AKI, acute kidney injury; HES, hydroxyethylstarch; RIFLE, Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and
End-stage kidney disease; SD, standard deviation.
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administered.
The HES used in prospective randomized studies were
intermediate molecular weight. In our unit, the HES is
of small molecular weight (130 kDa/0.4) with low sub-
stitution rate. Some studies suggest these ‘modern’ HES
are less nephrotoxic, in renal transplantation [33], and
in neurological intensive care[ 1 4 ] .T h el a t e s ts t u d y ,i n
patients with cranial trauma, did not find any difference
on renal function between patients receiving as much as
70 ml/kg/day HES 130 kDa/0.4 versus HES 200 kDa/0.5
33 ml/kg/day with additional albumin. A recent review
[34] confirmed the deleterious effects of older HES pre-
parations with high molecular weight and a high degree
of substitution administered in high volume and the
interest in tetrastarch solutions, probably less (or not at
all) nephrotoxic. According to these studies, the main
mechanism of HES-induced kidney injury is probably
hyperoncoticity: kidney lesions called osmotic nephrosis
associated with a decrease of glomerular filtration pres-
sure secondary to a more rapid increase in intracapillary
oncotic pressure than hydrostatic pressure. This theory
well explains the nephrotoxicity associated with HES
and serum albumin in a recent multicenter observa-
tional study [7]. This might also explain the low toxicity
of ‘modern’ HES solutions.
Study limitations
We performed a retrospective practice survey. Our
results do not support that HES are not nephrotoxic,
but suggest that in our daily practice, their use is not
directly associated with AKI. However, our results
must be taken with caution because this survey has
numerous biases. First, our groups are not homoge-
neous: HES group is composed of more severe
patients. As HES administration was not conducted
according to a protocol, attending physicians could
have generated a systematic bias with no HES use
when patients had renal failure or were at risk of AKI.
This seems improbable, because patients who received
HES had initial higher RIFLE classes and SOFA scores.
Second, considering the small HES volumes adminis-
tered, our study could lack power to demonstrate a
deleterious effect of HES on renal function. Third,
some could argue that we assessed AKI based on the
RIFLE classification, commonly used at the time we
designed our study, instead of the more recent Acute
Kidney Injury Network (AKIN) staging system [35].
This has probably no influence on our results, as
RIFLE ‘injury’ and ‘failure’ classes correspond to AKIN
staging system 2 and 3. Finally, as we used low substi-
tution rate HES, our results cannot be extrapolated to
other types of HES.
Conclusions
The nephrotoxicity of high molecular weight and high
substitution rate HES administered at high posology in
patients with severe sepsis and septic shock is demon-
strated by multiple studies. However, we suggest that
volume expansion with ‘modern’ HES and much lower
volumes than those recommended, is not associated
with AKI, even in patients with kidney dysfunction on
admission.
Key messages
￿ Resuscitation with low volume of HES 130 kDa/0.4
is not associated with AKI.
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